Safety and efficacy of alefacept in elderly patients and other special populations.

Abstract

BACKGROUND The safety of biologic agents for psoriasis treatment is of particular importance in patient groups at higher risk for adverse events. We assessed the safety and efficacy of alefacept in elderly, obese, and diabetic patients with moderate to severe chronic plaque psoriasis by integrating data from phase 2 and 3 clinical studies and their… (More)

Topics

Cite this paper

@article{Gottlieb2005SafetyAE, title={Safety and efficacy of alefacept in elderly patients and other special populations.}, author={Alice Bendix Gottlieb and W Henning Boehncke and Mohamed Darif}, journal={Journal of drugs in dermatology : JDD}, year={2005}, volume={4 6}, pages={718-24} }